COVID-19 疫情下的体外受精:新鲜辅助生殖技术周期的治疗结局
这项回顾性队列研究纳入以色列两个大型 IVF 中心的 121 例感染 SARS-CoV-2 后行新鲜 ART 周期的女性,按年龄匹配 121 例未诊断未接种对照。总体卵母细胞获数、成熟率、受精率、每周期冷冻胚胎数及临床妊娠率组间相似;取卵前感染超过 180 天可能对卵母细胞获数有长期负面影响,但样本量小。
要点
- 感染组与对照组新鲜 ART 周期的卵母细胞获数、成熟率、受精率、冷冻胚胎数及临床妊娠率相似。
- logistic 回归显示取卵前感染超过 180 天对卵母细胞获数有负面影响(P=0.018),但样本量小。
- 作者认为 SARS-CoV-2 感染不影响新鲜 ART 治疗结局,但需进一步研究支持。
核心结论
- SARS-CoV-2 感染不影响新鲜 ART 治疗结局,但取卵前感染超过 180 天可能对卵母细胞获数有长期负面影响。
研究设计与样本
- 回顾性队列研究,纳入 2020 年 10 月至 2021 年 6 月期间感染 SARS-CoV-2 后一年内(感染后第一个周期)行新鲜 ART 周期的女性,按年龄匹配未诊断未接种对照。
- 研究对象来自以色列两个大型 IVF 中心,共 121 例感染患者和 121 例对照。
主要发现
- 感染组与对照组卵母细胞获数分别为 12.50 与 11.29(P=0.169),成熟卵母细胞率分别为 78% 与 82%(P=0.144),差异无统计学显著。
- 受精率、每周期冷冻胚胎数及新鲜周期胚胎移植后的临床妊娠率(43% 与 40%;P=0.737)组间相似。
- logistic 回归模型中,取卵前感染超过 180 天对卵母细胞获数有负面影响(P=0.018,斜率=-4.08,95%CI -7.41 至 -0.75),但样本量小。
临床怎么用
- 作者认为 SARS-CoV-2 感染不影响新鲜 ART 治疗结局,但取卵前感染超过 180 天可能对卵母细胞获数有长期负面影响。
- 作者指出需进一步研究支持这些发现。
局限性
- 回顾性研究,数据并非在研究方案下统一生成。
- 对照组未进行抗体检测。
- 取卵前感染超过 180 天对卵母细胞获数有负面影响的回归分析样本量小。
- 需进一步研究支持这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does prior severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in women undergoing fertility treatments affect the outcomes of fresh ART cycles? SUMMARY ANSWER: SARS-CoV-2 infection does not affect fresh ART treatment outcomes, except for a possible long-term negative effect on oocyte yield (>180 days postinfection). WHAT IS KNOWN ALREADY: A single previous study suggested no evidence that a history of asymptomatic or mild SARS-CoV-2 infection in females caused impairment of fresh ART treatment outcomes. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study, including all SARS-CoV-2 infected women who underwent fresh ART cycles within a year from infection (the first cycle postinfection), between October 2020 and June 2021, matched to non-diagnosed controls. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients from two large IVF units in Israel who were infected with SARS-CoV-2 and later underwent fresh ART cycles were matched by age to non-diagnosed, non-vaccinated controls. Demographics, cycle characteristics and cycle outcomes, including oocyte yield, maturation rate, fertilization rate, number of frozen embryos per cycle and clinical pregnancy rates, were compared between groups. MAIN RESULTS AND THE ROLE OF CHANCE: One hundred and twenty-one infected patients and 121 controls who underwent fresh ART cycles were included. Oocyte yield (12.50 versus 11.29; P = 0.169) and mature oocyte rate (78% versus 82%; P = 0.144) in all fresh cycles were similar between groups, as were fertilization rates, number of frozen embryos per cycle and clinical pregnancy rates (43% versus 40%; P = 0.737) in fresh cycles with an embryo transfer. In a logistic regression model, SARS-CoV-2 infection more than 180 days prior to retrieval had a negative effect on oocyte yield (P = 0.018, Slope = -4.08, 95% CI -7.41 to -0.75), although the sample size was small. LIMITATIONS, REASONS FOR CAUTION: A retrospective study with data that was not uniformly generated under a study protocol, no antibody testing for the control group. WIDER IMPLICATIONS OF THE FINDINGS: The study findings suggest that SARS-CoV-2 infection does not affect treatment outcomes, including oocyte yield, fertilization and maturation rate, number of good quality embryos and clinical pregnancy rates, in fresh ART cycles, except for a possible long-term negative effect on oocyte yield when retrieval occurs >180 days post-SARS-CoV-2 infection. Further studies are warranted to support these findings. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: 0010-21-HMC, 0094-21-ASF.
引用
- Youngster M, Avraham S, Yaakov O, et al. IVF under COVID-19: treatment outcomes of fresh ART cycles. Hum Reprod. 2022. PMID: 35212741. doi:10.1093/humrep/deac043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。